Scarica l'app Stockscreener
6.90
0.00%
0.00
Pre-mercato:
6.91
0.010
+0.14%
Precedente Chiudi:
$6.90
Aprire:
$6.9
Volume 24 ore:
1.48M
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.19B
Reddito:
$314.85M
Utile/perdita netta:
$12.01M
Rapporto P/E:
105.34
EPS:
0.0655
Flusso di cassa netto:
$47.52M
1 W Prestazione:
+2.83%
1M Prestazione:
+10.58%
6M Prestazione:
-1.29%
1 anno Prestazione:
+51.98%
Intervallo 1D:
$6.785
$7.055
Intervallo di 1 settimana:
$6.61
$7.08
Portata 52W:
$4.4005
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.90 | 1.19B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Xeris Biopharma Holdings Inc. (XERS) Q1 2026 Earnings: Surprise EPS Profitability Achieved Amid Mixed Market ReceptionDownward Estimate Revision - newsline.com
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma - Insider Monkey
Xeris Pharmaceuticals, Inc. (XERS) stock price, news, quote and history - Yahoo Finance UK
Xeris Biopharma Stock (US98422E1038): Debt Exchange Targets $23 Million Of 8% Convertible Notes - AD HOC NEWS
XERS Receives Notice of Allowance for Patent on Keveyis - GuruFocus
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
XERS Enters Exchange Agreements to Retire Convertible Notes - GuruFocus
Xeris receives patent allowance for Keveyis through 2039 By Investing.com - Investing.com Canada
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® - lincolnjournal.com
Xeris Biopharma Announces Debt Exchange Agreement to Strengthen Balance Sheet - GuruFocus
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks - Insider Monkey
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Stock HigherPre-Announcement Alert - newsline.com
Xeris Biopharma to Retire $23 Million of Convertible Notes Through Private Exchange - marketscreener.com
Xeris to retire $23M of convertible notes through exchange agreements - MSN
Xeris Biopharma Announces Private Exchange of Convertible Notes - BioSpace
Xeris Biopharma (XERS) Retires $23M in Convertible Notes Through Exchange - GuruFocus
Xeris Biopharma to retire $23 million in convertible notes - Investing.com
Xeris Biopharma (NASDAQ: XERS) to retire $23M of 8% notes in cash-and-stock deal - Stock Titan
fastest-growing companies - Crain's Chicago Business
Xeris Biopharma (XERS) Surges 4%: Breaking Past Key Support with Upward MomentumMoving Average Crossovers - newsline.com
XERS Q1 2026 Earnings: EPS Surprise of 217.65% Drives Positive MomentumCapex Guidance - newsline.com
Xeris Biopharma Holdings (XERS) Edges Higher with Steady Support Levels HoldingCall Dominated - newsline.com
Xeris Biopharma director John Johnson sells $91,422 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock By Investing.com - Investing.com South Africa
Xeris Biopharma director John Johnson sells $91,422 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares - Investing.com UK
Xeris Biopharma director Marla Persky sells $91,432 in shares By Investing.com - Investing.com Australia
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock By Investing.com - Investing.com South Africa
Xeris Biopharma director Dawn Halkuff sells $121,885 in company stock - Investing.com
Xeris Biopharma (XERS) director awarded new RSU and stock option grants - Stock Titan
Xeris Biopharma (XERS) director logs stock sale and new equity grants - Stock Titan
Xeris Biopharma director Bormann-Kennedy sells $97,507 in stock - Investing.com
[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity - Stock Titan
Xeris Biopharma (XERS) director trades stock and receives new equity awards - Stock Titan
Xeris Biopharma (XERS) director gets equity grant and 10b5-1 share sale - Stock Titan
Xeris Biopharma (XERS) director receives new RSU and stock option grants - Stock Titan
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor - TipRanks
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event - Stock Titan
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
XERS: RECORLEV drives robust growth as pipeline and commercial expansion accelerate, with strong financials - TradingView
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trade - Stock Titan
XERS Q1 2026 Earnings: Surprise Profitability at Odds with Market SentimentGross Profit Margin - newsline.com
XERS Q1 2026 Earnings: EPS Beat Masks Cautious Outlook as Shares DipEarnings Yield Spread - newsline.com
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS) - Seeking Alpha
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xeris Biopharma Holdings Inc Azioni (XERS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HALKUFF DAWN | Director |
Jun 04 '26 |
Sale |
6.09 |
20,000 |
121,886 |
95,000 |
| BORMANN-KENNEDY BARBARA-JEAN A | Director |
Jun 04 '26 |
Sale |
6.09 |
16,000 |
97,507 |
126,500 |
| JOHNSON JOHN | Director |
Jun 04 '26 |
Sale |
6.09 |
15,000 |
91,422 |
683,083 |
0.95%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):